T24細(xì)胞 
	
		生長(zhǎng)狀態(tài):	貼壁生長(zhǎng)
	
	
		年限:	81 years
	
	
		細(xì)胞形態(tài):	上皮樣
	
	
		數(shù)量:	大量
	
	
		器官來(lái)源:	膀胱
	
	
		是否是腫瘤細(xì)胞:	1
	
	
		物種來(lái)源:	人
	
	
		運(yùn)輸方式:	凍存運(yùn)輸
	
	
		ATCC Number:	HTB-4?
	
	
		相關(guān)**:	移行細(xì)胞癌
	
	
		Designations:	T24
	
	
		Depositors:	 C O'Toole
	
	
		T24細(xì)胞Biosafety Level:	1
	
	
		Shipped:	frozen
	
	
		Medium & Serum:	See Propagation
	
	
		Growth Properties:	adherent
	
	
		Organism:	Homo sapiens
	
	
		Morphology:	epithelial
	
	
		
	
	
		Source:	Organ: urinary bladder
	
	
		Disease: transitional cell carcinoma
	
	
		Cellular Products:	tumor specific antigen
	
	
		Permits/Forms:	In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
	
	
		Applications:	transfection host
	
	
		Tumorigenic:	Yes
	
	
		Antigen Expression:	HLA A1, A3, B18, Bw35, Cw4, DRw2, Dw4
	
	
		DNA Profile (STR):	Amelogenin: X
	
	
		CSF1PO: 10,12
	
	
		D13S317: 12
	
	
		D16S539: 9
	
	
		T24細(xì)胞D5S818: 10,12
	
	
		D7S820: 10,11
	
	
		THO1: 6
	
	
		TPOX: 8,11
	
	
		vWA: 17
	
	
		Cytogenetic Analysis:	hypodiploidy to hypopentaploidy; stemline 86; 2 to 4 telocentrics; 3 to 4 minutes, hypotetraploid to hypertetraploid with abnormalities including dicentrics, breaks, pulverization, minutes and telocentric markers
	
	
		Isoenzymes:	AK-1, 1
	
	
		ES-D, 1
	
	
		G6PD, B
	
	
		GLO-I, 1
	
	
		Me-2, 1-2
	
	
		PGM1, 1
	
	
		PGM3, 1
	
	
		Age:	81 years
	
	
		Gender:	female
	
	
		Ethnicity:	Caucasian
	
	
		Comments:	Leukocytes and sera from patients with transitional cell carcinoma were cytotoxic to T24 and related lines.
	
	
		Cells have a 19 hour generation time.
	
	
		Contains the ras (H-ras) oncogene.
	
	
		Propagation: T24細(xì)胞ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
	
	
		Temperature: 37.0°C
	
	
		Subculturing:	Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended
	
	
		Medium Renewal: 2 to 3 times per week
	
	
		Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
	
	
		Add fresh culture medium, aspirate and dispense into new culture flasks.
	
	
		Preservation:	Culture medium, 95%; DMSO, 5%
	
	
		Related Products:	recommended serum:ATCC 30-2020
	
	
		References:	21849: O'Toole CHuman bladder cancer lines: HLA Class I and Class II antigen expression and susceptibility to cytostatic and cytotoxic effects in vitroIn: O'Toole CIn vitro models for cancer researchvol. IVBoca Raton, FLCRC Presspp. 103-125.
	
	
		22365: O'Toole C, et al. Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy. Int. J. Cancer 10: 77-91, 1972. PubMed: 4196436
	
	
		22443: Williams BY, Schonbrunn A. Bombesin receptors in a human duodenal tumor cell line: binding properties and function. Cancer Res. 54: 818-824, 1994. PubMed: 8306345
	
	
		22510: Bubenik J, et al. Cellular and humoral immune responses to human urinary bladder carcinomas. Int. J. Cancer 5: 310-319, 1970. PubMed: 5452065
	
	
		22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871
	
	
		22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080
	
	
		22849: Bubenik J, et al. T24細(xì)胞Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int. J. Cancer 11: 765-773, 1973. PubMed: 4133950
	
	
		23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212
	
	
		23256: Carey TE, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc. Natl. Acad. Sci. USA 73: 3278-3282, 1976. PubMed: 1067619
	
	
		24381: Fogh J. Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors. Natl. Cancer Inst. Monogr. 49: 5-9, 1978. PubMed: 571047
	
	
		25065: Bellet D, et al. Malignant transformation of nontrophoblastic cells is associated with the expression of chorionic gonadotropin beta genes normally transcribed in trophoblastic cells. Cancer Res. 57: 516-523, 1997. PubMed: 9012484
	
	
		26316: Bubenik J, et al. Cellular immunity to renal carcinomas in man. Int. J. Cancer 8: 503-513, 1971. PubMed: 5137312
	
	
		32266: Bender CM, et al. Inhibition of DNA methylation by 5-Aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58: 95-101, 1998. PubMed: 9426064
	
	
		33025: Ponton A, et al. The CD95 (APO-1/Fas) receptor activates NF-kappaB independently of its cytotoxic function. J. Biol. Chem. 271: 8991-8995, 1996. PubMed: 8621545